Campaigners for and against assisted dying make feelings known at Westminster
Dame Prue Leith, Dame Esther Rantzen's daughter, Rebecca Wilcox, and the broadcaster, Jonathan Dimbleby, were among the high-profile figures supporting the Bill to change the law in England and Wales.
Members of the Dignity in Dying campaign wore pink and held placards in memory of friends and family members.
Those opposed to the Bill included groups dressed as scientists in white lab coats and bloodied gloves and masks, as well as nuns and other members of religious organisations.
The mood amongst campaigners was largely calm and respectful on both sides.
Dame Prue told the PA news agency she was 'both nervous and confident' about the outcome.
'It's so moving to see all these people with placards of people they've lost or people who are dying of cancer,' she said.
'It's hard not to cry because I think they have done such a good job. Let's hope we've won.'
Mr Dimbleby said he believed the Bill would be 'transformative'.
He added: 'What it will mean is millions of people will be able to say to themselves, 'If I'm terminally ill, I will be able to choose, assuming I am of sound mind and I am not being coerced, to say 'Yes, I want to be assisted – I have dignity in death'.'
Rebecca Wilcox, the daughter of Dame Esther, said: 'It couldn't be a kinder, more compassionate Bill that respects choice at the end of life, that respects kindness and empathy and gives us all an option when other options, every other option, has been taken away, and it would just be the perfect tool for a palliative care doctor to have in their med bag.'
Teachers Catie and Becky Fenner said they wanted other families to benefit from the Bill.
Their mother, who had motor neurone disease, had flown to Dignitas in Switzerland to end her life at a cost of £15,000. The sisters said they did not get to properly say goodbye and grieve and worried about the legal repercussions.
Catie, 37, said: 'We were left quite traumatised by the whole experience – not only seeing a parent go through a really horrible disease but then the secrecy of the planning.'
Campaigners against the Bill, who were gathered outside Parliament, chanted 'We are not dead yet' and 'Kill the Bill, not the ill'.
A display was erected with a gravestone reading 'RIP: The Terminally Ill Adults (End of Life) Bill. Bury it deep', and behind were two mounds meant to resemble graves.
Andrew Hilliard, 75, said he was opposed for religious reasons. He was dressed in a white lab coat with a placard reading: 'Protect our NHS from becoming the National Suicide Service'.
The chief executive of Care Not Killing, Dr Gordon Macdonald, said MPs should prioritise improving palliative care.
He said: 'Most people, when thinking about the practical implications of this, for those most vulnerable, they change their minds.'
George Fielding, a campaigner affiliated with the Not Dead Yet group which is opposed to assisted dying, said he attended to represent disabled people.
He said: 'This Bill will endanger and shorten the lives of disabled people.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
EXCLUSIVE England's most depressed streets revealed - so how high are rates in YOUR neighbourhood?
England's depression capitals are today revealed in MailOnline's interactive map of every neighbourhood in the country. Topping the table of 34,000 districts, according to the House of Commons Library's (HoC) figures, comes a suburb of Stockport in Greater Manchester. Nearly one in three GP patients in that particular enclave of Brinnington, located just off the M60, have been diagnosed with depression. At the other end of the scale, just 3.5 per cent of people living in an affluent zone of Knightsbridge, central London, are thought to suffer with the mental illness. Five-story Edwardian homes which sell for north of £1.5million are commonplace in that precinct, just a ten-minute walk from Harrods. Our map, which allows you to zoom into street level, plots the depression prevalence estimates for all 34,000 lower super output areas (LSOA) in England – tiny pockets of the country made up of around 1,000 and 3,000 people. Each LSOA is coloured by how many GP patients aged over 18 have been diagnosed with depression. The darker the shade of red, the higher the rate of sufferers. The figure for the entirety of England stood at around 13 per cent, slightly higher than official estimates. Depression is 'more than simply feeling unhappy or fed up for a few days' and is 'not something you can snap out of', the advice page from the NHS states. Of the ten LSOAs with the highest rates of depression, eight were located in the north of England, specifically in Stockport and the Wirral. The other two were in Plymouth's deprived Budshead community, where locals have bemoaned a rise in anti-social behaviour from children who have 'nothing to do'. Eight of the ten places with the lowest rates of depression were in the local authority of Westminster. Dr Dalia Tsimpida, lecturer in gerontology at the University of Southampton, has been investigating what makes some neighbourhoods mental health hotspots while others remain relatively protected. She said: 'Our research reveals a complex web of environmental and socioeconomic factors that contribute to higher depression rates in certain areas. 'Deprivation is a key driver, accounting for up to 39 per cent of recorded depression levels across England, although this varies dramatically by location.' Her research has identified a previously overlooked factor: noise pollution. Areas with transportation noise exceeding 55 decibels on average in a 24-hour basis show much stronger links between health deprivation, disability, and depression. 'Environmental stressors play a crucial but underappreciated role,' she said. 'While transportation noise doesn't directly cause depression, it significantly amplifies the impact of other risk factors.' Dr Tsimpida added: 'Living in a depression hotspot exposes people to what may be "contagion effects" - both social and environmental. 'We observed that mental health challenges may spread through communities through mechanisms like social isolation, reduced community resources, environmental degradation, and normalised hopelessness.' Studies suggest depression rates can be linked to other factors, such as low income or living alone, according to the Adult Psychiatric Morbidity Survey. The survey, carried out for the NHS, also showed a link between poor physical health and mental knock-on effects. Dr Tsimpida added: 'Areas with lower depression rates – particularly in London and the South East – benefit from multiple protective factors working together. 'These include better economic opportunities, higher-quality housing, more green spaces, lower environmental stressors, and stronger social infrastructure.' What is depression? While it is normal to feel down from time to time, people with depression may feel persistently unhappy for weeks or months on end. Depression can affect anyone at any age and is fairly common - approximately one in ten people are likely to experience it at some point in their life. Depression is a genuine health condition which people cannot just ignore or 'snap out of it'. Symptoms and effects vary, but can include constantly feeling upset or hopeless, or losing interest in things you used to enjoy. It can also cause physical symptoms such as problems sleeping, tiredness, having a low appetite or sex drive, and even feeling physical pain. In extreme cases it can lead to suicidal thoughts. Traumatic events can trigger it, and people with a family history may be more at risk. It is important to see a doctor if you think you or someone you know has depression, as it can be managed with lifestyle changes, therapy or medication. Source: NHS Choices A House of Commons report last year estimated that one in six adults experienced a 'common mental disorder' like depression or anxiety in the previous week. But when it comes to treatment, there is a postcode lottery as waiting times for NHS talking therapies (TTAD). Sufferers in Gloucestershire can be seen in just four days, while others in Southport and Formby have to wait at least 10 weeks. Two-thirds of people experience improvement after TTAD, but this varies in different parts of England and between social groups. Health service figures show a record 8.7million people in England, about 15 per cent of the total population, are now on antidepressants, which can also be given to fight OCD, anxiety and PTSD. Some experts have been concerned about the 'one size fits all' approach to patients suffering from depression. The concerns have mainly focused on the use of a type of selective serotonin reuptake inhibitors (SSRIs) and its libido crushing side-effects. Some users have reported being transformed into 'sexless' zombies even years after they stopped taking the mind-altering pills. Uptake of the pills has soared in recent years despite growing unease among experts about the effectiveness of the drugs in treating depression. Plenty of patients insist they work, however. Psychiatrists urge patients concerned about side effects, or potential consequences, of antidepressants to talk to their medical professional about their options. Earlier this year, one of the UK's most eminent GPs warned thousands of Brits were mistaking the 'normal stresses of life' for mental health problems — and incorrectly diagnosing themselves with psychiatric conditions. Dame Clare Gerada, former president of the Royal College of General Practitioners, told MailOnline in January that Britain has a 'problem' with people 'seeking labels to explain their worries'. Professor Gerada's concerns echo that of former Prime Minister Sir Tony Blair's, who has warned against over-medicalising the 'ups and downs of life'. Sir Tony, who served as PM from 1997 to 2007, said there was a danger of telling too many people going through life's normal challenges that they are suffering a mental health condition. Dr Tsimpida argues that current approaches to tackling depression may be fundamentally flawed because they focus on treating individuals rather than transforming places. She said: 'We need place-based interventions, not just individual treatments. 'Our findings show that traditional randomised controlled trials may miss crucial spatial influences on mental health outcomes.' Based on her research findings, she suggests several priority actions which include noise mitigation strategies, sustained investment in hotspots and integrated approaches to treat all root causes at the same time. She added: 'The key insight from our research is that treating depression effectively requires changing places, not just treating people. Jen Dykxhoorn, a research fellow at University College London's Division of Psychiatry Neighbourhood believes regeneration programmes may be helpful. She said: 'There is some evidence that initiatives like planting trees, removing litter, and improving the physical quality of neighbourhoods can reduce rates of depression.' MailOnline's investigation into the country's depression hotspots was calculated from House of Commons Library data which was compiled from GP practice registers in England as published by NHS Digital. Some apparent variation between areas may be explained by differences in how GPs operate and measure, rather than genuine differences in the prevalence of disease and health conditions. HoC Library's most up to date figures use the 2011 LSOA boundaries which were updated in 2021.
BBC News
an hour ago
- BBC News
Film premiering in Redruth aims to help deaf people with diabetes
A series of new educational films are aiming to help deaf people and those with hearing loss access diabetes British Sign Language (BSL) films premiered at the Regal Cinema in Redruth and hope to improve understanding of diabetes and help deaf people navigate healthcare were produced by NHS Cornwall and Isles of Scilly (NHSCIOS), Diabetes UK, Hearing Loss Cornwall and members of the deaf community and will be shown across the UK by health said an estimated one in five people in the region are deaf or have some level of hearing loss while Diabetes UK said around 48,000 in the county live with diabetes. 'No one is left behind' Dr Chris Reid, chief medical officer for NHSCIOS, said it could be "a huge challenge" for people who are deaf or live with hearing loss to access health said: "By creating these films in British Sign Language we are not only breaking down barriers, we are helping to make sure that no one is left behind when it comes to understanding, managing and living well with diabetes. "This is about doing healthcare differently – because everyone deserves the same chance to live a healthy life."Chris Gould who has type 2 diabetes and is deaf said: "Having information in BSL, at last, is exciting for the deaf community, as it shows that the needs of the deaf community are being taken seriously."It's been long awaited, and I hope we can develop more to include deaf people to bring long overdue equality."
Wales Online
an hour ago
- Wales Online
The new weight loss pill showing significant results within 12 weeks
The new weight loss pill showing significant results within 12 weeks The weight loss pill has showed promise in new trials with some reporting up to 24% weight loss The experimental drug tests have shown up to 24% weight loss (Image: PA ) An early study has found that a new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight. It has found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Stay informed on the latest health news by signing up to our newsletter here Article continues below Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body - GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. "These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity," the authors wrote. "Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment." The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Article continues below Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
